Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Aquestive Therapeutics, Inc. incurred credit facility of up to $150.0 million with Oaktree Fund Administration, LLC, as administrative agent, and certain funds managed by Oaktree Capital Management, L.P. as Lenders at three-month SOFR (with a floor of 2.75%) plus 6.25% maturing five years from the closing date.
- Instrument
- credit facility
- Principal
- up to $150.0 million
- Counterparty
- Oaktree Fund Administration, LLC, as administrative agent, and certain funds managed by Oaktree Capital Management, L.P. as Lenders
- Rate
- three-month SOFR (with a floor of 2.75%) plus 6.25%
- Maturity
- five years from the closing date
- Event
- incurrence
Exact text from the filing
On May 12, 2026 (the “Effective Date”), Aquestive Therapeutics, Inc. (the “Company”) entered into a five-year term loan facility of up to $150.0 million (the “Term Loan”), consisting of a term loan in an aggregate principal amount of $55.0 million that was funded on the Effective Date (the “Tranche A Term Loan”), a term loan in an aggregate principal amount of $20.0 million available subject to certain terms and conditions (the “Tranche B Term Loan”), a term loan in an aggregate principal amount of $25.0 million available subject to certain terms and conditions (the “Tranche C Term Loan”), and a term loan advance available upon the mutual consent of the Lenders and subject to certain terms and conditions in an aggregate principal amount of up to $50.0 million (the “Tranche D Term Loan”), pursuant to a credit agreement and guaranty, dated as of the Effective Date (the “Credit Agreement”), with Oaktree Fund Administration, LLC, a Delaware limited liability company, as administrative agen
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Aquestive Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.
- Period
- first quarter ended March 31, 2026
- Result
- reported results
Exact text from the filing
On May 13, 2026, Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing its reported financial results for the first quarter ended March 31, 2026 and provided an update on recent developments in its business.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Aquestive Therapeutics, Inc. entered into Credit Agreement with Oaktree Fund Administration, LLC, as administrative agent, and certain funds managed by Oaktree Capital Management, L.P. valued at term loan facility of up to $150.0 million (effective 2026-05-12).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Oaktree Fund Administration, LLC, as administrative agent, and certain funds managed by Oaktree Capital Management, L.P.
- Value
- term loan facility of up to $150.0 million
- Effective
- 2026-05-12
Exact text from the filing
On May 12, 2026 (the “Effective Date”), Aquestive Therapeutics, Inc. (the “Company”) entered into a five-year term loan facility of up to $150.0 million (the “Term Loan”)
View on SEC.gov